What is claimed is:

1. An isolated antibody molecule capable of binding to human T-cell immunoglobulin domain and mucin domain 3 (TIM-3), comprising:

(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 10; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(b) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 4; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(c) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 25; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(d) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 24; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(e) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 31; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14; or

(f) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 30; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a

VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

2. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 10; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14.

3. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 4; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

4. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 25; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14.

5. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 24; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

6. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 31; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a

VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14.

7. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 30; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

8. The antibody molecule of any of claims 1-7, wherein said antibody molecule is a humanized antibody molecule.

9. The antibody molecule of any of claims 1-8, wherein said antibody molecule is a monospecific antibody molecule.

10. The antibody molecule of any of claims 1-8, wherein said antibody molecule is a bispecific antibody molecule.

11. The antibody molecule of claim 10, wherein said antibody molecule has a first binding specificity for TIM-3 and a second binding specificity for PD-1, LAG-3, CEACAM-1, CEACAM-5, PD-L1 or PD-L2.

12. The antibody molecule of any of claims 1-11, wherein said antibody molecule comprises an antigen binding fragment of an antibody.

13. The antibody molecule of claim 12, wherein said antibody molecule comprises a half antibody or antigen binding fragment of a half antibody.

14. The antibody molecule of any of claims 1-13, which is a Fab, F(ab')2, Fv, or a single chain Fv fragment (scFv).

15. The antibody molecule of any of claims 1-14, which binds an IgV domain of TIM-3.

16. The antibody molecule of any of claims 1-15, which comprises a heavy chain variable domain comprising an amino acid sequence at least 85% identical to any of SEQ ID NOs: 1, 16, 26, 32, 36, 44, 48, 52, 60, 68, 72, 76, 80, 84, 92, or 100.

17. The antibody molecule of any of claims 1-16, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 1, 16, 26, 32, 36, 44, 48, 52, 60, 68, 72, 76, 80, 84, 92, or 100.

18. The antibody molecule of any of claims 1-17, which comprises a light chain variable domain comprising an amino acid sequence at least 85% identical to any of SEQ ID NOs: 2, 20, 40, 56, 64, 88, 96, or 104.

19. The antibody molecule of any of claims 1-18, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 2, 20, 40, 56, 64, 88, 96, or 104.

20. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 1.

21. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16.

22. The antibody molecule of any of claims 1-21, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 121.

23. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26.

24. The antibody molecule of any one of claims 1-19 or 23, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 28.

25. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 32.

26. The antibody molecule of any one of claims 1-19 or 25, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 34.

27. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 36.

28. The antibody molecule of any one of claims 1-19 or 27, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 38 or SEQ ID NO: 116.

29. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 44.

30. The antibody molecule of any one of claims 1-19 or 29, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 46.

31. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 48.

32. The antibody molecule of any one of claims 1-19 or 31, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 50.

33. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 52.

34. The antibody molecule of any one of claims 1-19 or 33, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 54.

35. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60.

36. The antibody molecule of any one of claims 1-19 or 35, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 62.

37. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 68.

38. The antibody molecule of any one of claims 1-19 or 37, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 70.

39. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 72.

40. The antibody molecule of any one of claims 1-19 or 39, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 74.

41. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76.

42. The antibody molecule of any one of claims 1-19 or 41, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 78.

43. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80.

44. The antibody molecule of any one of claims 1-19 or 43, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 82.

45. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 84.

46. The antibody molecule of any one of claims 1-19 or 45, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 86.

47. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 92.

48. The antibody molecule of any one of claims 1-19 or 47, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 94.

49. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 100.

50. The antibody molecule of any one of claims 1-19 or 49, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102.

51. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

52. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

53. The antibody molecule of any of claims 1-52, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 22.

54. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

55. The antibody molecule of any of claims 1-50 or 54, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 42.

56. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

57. The antibody molecule of any of claims 1-50 or 56, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 58.

58. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

59. The antibody molecule of any of claims 1-50 or 58, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 66.

60. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88.

61. The antibody molecule of any of claims 1-50 or 60, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 90.

62. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 96.

63. The antibody molecule of any of claims 1-50 or 62, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 98.

64. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 104.

65. The antibody molecule of any of claims 1-50 or 64, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 106.

66. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

67. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

68. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

69. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 32 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

70. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

71. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 44 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

72. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 48 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

73. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

74. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

75. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

76. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

77. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

78. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

79. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

80. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 72 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

81. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

82. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

83. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

84. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 72 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

85. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

86. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

87. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 84 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88.

88. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 96.

89. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 100 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 104.

90. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

91. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 28 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

92. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 34 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

93. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain comprising the amino acid sequence of SEQ ID NO: 42.

94. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 46 and a light chain comprising the amino acid sequence of SEQ ID NO: 42.

95. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 50 and a light chain comprising the amino acid sequence of SEQ ID NO: 42.

96. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 116 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

97. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 42.

98. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 54 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

99. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 62 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

100. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 54 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

101. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 62 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

102. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 70 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

103. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 74 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

104. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 78 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

105. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 82 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

106. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 70 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

107. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 74 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

108. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 78 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

109. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 82 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

110. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 86 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

111. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 94 and a light chain comprising the amino acid sequence of SEQ ID NO: 98.

112. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 106.

113. The antibody molecule of any of claims 1-112, which comprises a heavy chain constant region selected from IgG1, IgG2, IgG3, and IgG4.

114. The antibody molecule of claim 113, which comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda.

115. The antibody molecule of claim 113 or 114, which comprises a human IgG4 heavy chain constant region with a mutation at position 228 according to EU numbering or position 108 of SEQ ID NO: 108 or 110 and a kappa light chain constant region.

116. The antibody molecule of claim 113 or 114, which comprises a human IgG4 heavy chain constant region with a Serine to Proline mutation at position 228 according to EU numbering or position 108 of SEQ ID NO: 108 or 110 and a kappa light chain constant region.

117. The antibody molecule of claim 113 or 114, which comprises a human IgG1 heavy chain constant region with an Asparagine to Alanine mutation at position 297 according to EU numbering or position 180 of SEQ ID NO: 112 and a kappa light chain constant region.

118. The antibody molecule of claim 113 or 114, which comprises a human IgG1 heavy chain constant region with an Aspartate to Alanine mutation at position 265 according to EU numbering or position 148 of SEQ ID NO: 113 and Proline to Alanine mutation at position 329 according to EU numbering or position 212 of SEQ ID NO: 113, and a kappa light chain constant region.

119. The antibody molecule of claim 113 or 114, which comprises a human IgG1 heavy chain constant region with a Leucine to Alanine mutation at position 234 according to EU numbering or position 117 of SEQ ID NO: 114 and Leucine to Alanine mutation at position 235 according to EU numbering or position 118 of SEQ ID NO: 114, and a kappa light chain constant region.

120. The antibody molecule of any of claims 1-118, which is capable of binding to human TIM-3 with a dissociation constant (K_D) of less than about 0.5 nM.

121. The antibody molecule of any of claims 1-120, which is capable of reducing binding of TIM-3 to PtdSer, HMGB1, CEACAM-1, or a combination thereof, or a cell that expresses PtdSer, HMGB1, CEACAM-1, or a combination thereof.

122. The antibody molecule of any of claims 1-121, which is capable of enhancing an antigen-specific T cell response.

123. An isolated antibody molecule that competes with a monoclonal antibody for binding to human T-cell immunoglobulin domain and mucin domain 3 (TIM-3), wherein the monoclonal antibody comprises:

(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 10; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(b) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 4; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(c) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 25; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(d) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 24; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(e) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 31; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14; or

(f) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 30; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

124. An isolated antibody molecule that binds to the same epitope as, substantially the same epitope as, an epitope that overlaps, or an epitope that substantially overlaps, the epitope of a monoclonal antibody to human T-cell immunoglobulin domain and mucin domain 3 (TIM-3), wherein the monoclonal antibody comprises:

(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 10; and a

VHCDR3 amino acid sequence of SEQ ID NO: 5; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(b) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 4; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(c) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 25; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(d) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 24; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(e) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 31; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14; or

(f) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 30; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

125. The antibody molecule of claim 123 or 124, wherein the antibody molecule binds to one, two, three, or all of: the two residues adjacent to the N-terminus of the A strand (Val24 and Glu25 in human TIM-3), the BC loop, the CC' loop, or the G strand of human TIM-3.

126. The antibody molecule of any of claims 123-125, wherein the antibody molecule further binds to one, two, three, or all of: the A strand, the EF loop, the F strand, or the FG loop.

127. The antibody molecule of any of claims 123-126, wherein the antibody molecule further binds to one, two, three, or all of: the third residue N-terminal to the A strand (Glu23 in human TIM-3), the C strand, the C'C'' loop, or the C'' strand.

128. The antibody molecule of any of claims 123-127, wherein the antibody molecule binds to one or both of residues Val24 and Glu25 adjacent to the N-terminus of the A strand; residue Thr41 within the BC loop; four, five, six, seven, or all of residues Glu121, Lys122, Phe123, Asn124, Leu125, Lys126, Leu127, and Val128 within the G strand; and three, four, five, or all of residues Gly56, Ala57, Cys58, Pro59, Val60, and Phe61 within the CC' loop.

129. The antibody molecule of any of claims 123-128, wherein the antibody molecule binds to residues Val24 and Glu25 adjacent to the N-terminus of the A strand; residue Thr41 within the BC loop; residues Glu121, Lys122, Phe123, Asn124, Leu125, Lys126, Leu127, and Val128 within the G strand; and residues Gly56, Ala57, Cys58, Pro59, Val60, and Phe61 within the CC' loop.

130. The antibody molecule of any of claims 123-129, wherein the antibody molecule further binds to one or more residues chosen from: residue Tyr26 within the A strand, residues Phe39 and Tyr40 within the BC loop; residue Ser105 within the EF loop; residues Gly106 and Ile107 within the F strand; and residues Asn119 and Asp120 within the FG loop.

131. The antibody molecule of any of claims 123-130, wherein the antibody molecule further binds to residue Tyr26 within the A strand, residues Phe39 and Tyr40 within the BC loop; residue Ser105 within the EF loop; residues Gly106 and Ile107 within the F strand; and residues Asn119 and Asp120 within the FG loop.

132. The antibody molecule of any of claim 123-131, wherein the antibody molecule further binds to one or more residues chosen from: residue Glu23 N-terminal to the A strand; residues Pro42, Ala43, Ala44, Pro45, Gly46, Asn47, Leu48, Val49, and Pro50 within the BC loop; residues Val51, Cys52, Trp53, Gly54, and Lys55 within the C strand; residues Arg73 and Asp74 with the C'C'' loop; and residues Val75, Asn76, and Tyr77 in the C'' strand.

133. The antibody molecule of any of claim 123-132, wherein the antibody molecule further binds to residue Glu23 N-terminal to the A strand; residues Pro42, Ala43, Ala44, Pro45, Gly46, Asn47, Leu48, Val49, and Pro50 within the BC loop; residues Val51, Cys52, Trp53, Gly54, and Lys55 within the C loop; residues Arg73 and Asp74 with the C'C'' strand; and residues Val75, Asn76, and Tyr77 in the C'' strand.

134. The antibody molecule of any of claims 123-133, wherein the antibody molecule reduces PtdSer-dependent membrane penetration of TIM-3.

135. The antibody molecule of any of claims 123-134, wherein the antibody molecule reduces binding of TIM-3 to one, two, or all of PtdSer, HMGB1, or CEACAM-1.

136. The antibody molecule of any of claims 123-135, wherein the antibody molecule does not inhibit binding of TIM-3 to Galectin-9.

137. The antibody molecule of any of claims 123-136, wherein the antibody molecule competes with CEACAM-1 for binding to one, two, or all of Cys58, Asn119 and Lys122 of TIM-3.

138. The antibody molecule of claim 137, wherein the antibody molecule reduces the formation of a hydrogen bond between Lys122 of TIM-3 and Asn42 of CEACAM-1.

139. The antibody molecule of any of claims 123-138, wherein the antibody molecule competes with PtdSer for binding to the FG loop and the CC' loop of TIM-3.

140. The antibody molecule of any of claims 123-139, wherein the antibody molecule competes with HMGB1 for binding to Glu62 of TIM-3.

141. The antibody molecule of any of claims 123-140, wherein the antibody molecule does not compete with Galectin-9 for binding to TIM-3.

142. A pharmaceutical composition comprising the isolated antibody molecule of any of claims 1-141 and a pharmaceutically acceptable carrier, excipient or stabilizer.

143. An isolated nucleic acid encoding the antibody heavy or light chain variable region of the antibody molecule of any of claims 1-141.

144. An isolated nucleic acid encoding heavy chain CDRs 1-3, wherein said nucleic acid comprises a nucleotide sequence encoding SEQ ID NOs: 3, 9, 4, 10, 24, 25, 30, 31, or 5.

145. An isolated nucleic acid encoding light chain CDRs 1-3, wherein said nucleic acid comprises a nucleotide sequence encoding SEQ ID NOs: 6, 12, 7, 13, 8, or 14.

146. The nucleic acid of claim 144, further comprising a nucleotide sequence encoding a heavy chain variable domain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 11, 17, 29, 33, 37, 45, 49, 53, 61, 69, 73, 77, 81, 85, 93, 101, 115, or 120.

147. The nucleic acid of claim 146, further comprising a nucleotide sequence encoding a heavy chain variable domain, wherein said nucleotide sequence comprises any of SEQ ID NO: 11, 17, 29, 33, 37, 45, 49, 53, 61, 69, 73, 77, 81, 85, 93, 101, 115, or 120.

148. The nucleic acid of claim 144, further comprising a nucleotide sequence encoding a heavy chain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 19, 29, 35, 39, 47, 51, 55, 63, 71, 75, 79, 83, 87, 95, 103, 117, or 122.

149. The nucleic acid of claim 148, further comprising a nucleotide sequence encoding a heavy chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 19, 29, 35, 39, 47, 51, 55, 63, 71, 75, 79, 83, 87, 95, 103, 117, or 122.

150. The nucleic acid of claim 145, which further comprises a nucleotide sequence encoding a light chain variable domain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 15, 21, 41, 57, 65, 89, 97, 105, 118, 123, 125, or 127.

151. The nucleic acid of claim 150, which further comprises a nucleotide sequence encoding a light chain variable domain, wherein said nucleotide sequence comprises any of SEQ ID NO: 15, 21, 41, 57, 65, 89, 97, 105, 118, 123, 125, or 127.

152. The nucleic acid of claim 145, further comprising a nucleotide sequence encoding a light chain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 23, 43, 59, 67, 91, 99, 107, 119, 124, 126, 128.

153. The nucleic acid of claim 152, further comprising a nucleotide sequence encoding a light chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 23, 43, 59, 67, 91, 99, 107, 119, 124, 126, 128.

154. An expression vector comprising the nucleic acid of any of claims 143-153.

155. A host cell comprising the nucleic acid of any of claims 143-153.

156. A method of producing an antibody molecule or fragment thereof, comprising culturing the host cell of claim 155 under conditions suitable for gene expression.

157. A method of stimulating an immune response in a subject, comprising administering to a subject in need thereof an isolated antibody molecule of any of claims 1-141, or a pharmaceutical composition of claim 142, in an amount effective to stimulate the immune response.

158. A method of treating a cancer, comprising administering to a subject in need thereof an isolated antibody molecule of any of claims 1-141, or a pharmaceutical composition of claim 142, in an amount effective to treat the cancer.

159. The method of claim 158, wherein the cancer is chosen from a lung cancer, a squamous cell lung cancer, a melanoma, a renal cancer, a breast cancer, an IM-TN breast cancer, a colorectal cancer, a leukemia, or a metastatic lesion of the cancer.

160. The method of any of claims 157-159, wherein the antibody molecule is administered in combination with a second therapeutic agent or procedure.

161. The method of claim 160, wherein the second therapeutic agent or procedure is chosen from one or more of chemotherapy, a targeted anti-cancer therapy, an oncolytic drug, a cytotoxic agent, an immune-based therapy, a cytokine, surgical procedure, a radiation procedure, an activator of a costimulatory molecule, an inhibitor of an inhibitory molecule, a vaccine, or a cellular immunotherapy.

162. The method of claim 160 or 161, wherein the antibody molecule is administered in combination with an agonist of a costimulatory molecule chosen from one or more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand.

163. The method of claim 160 or 161, wherein the antibody molecule is administered in combination with an inhibitor of an immune checkpoint molecule chosen from one or more of PD-1, PD-L1, PD-L2, CTLA-4, LAG-3, CEACAM-1, CEACAM-5, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR.

164. A method of treating an infectious disease, comprising administering to a subject in need thereof an isolated antibody molecule of any of claims 1-141, or a pharmaceutical composition of claim 142, in an amount effective to treat the infectious disease.

165. A method of detecting TIM-3 in a biological sample, comprising (i) contacting the sample or the subject (and optionally, a reference sample or subject) with an isolated antibody molecule of any of claims 1-141 under conditions that allow interaction of the antibody molecule and the polypeptide to occur, and (ii) detecting formation of a complex between the antibody molecule and the sample or the subject (and optionally, the reference sample or subject).

166. An antibody molecule of any of claims 1-141, or a pharmaceutical composition of claim 142, for use in treating a cancer or an infectious disease in a subject.

167. Use of an antibody molecule of any of claims 1-141, or a pharmaceutical composition of claim 142, in the manufacture of a medicament for treating a cancer or an infectious disease in a subject.

AMENDED CLAIMS
received by the International Bureau on 02 July 2015 (02.07.2015)

What is claimed is:

1. An isolated antibody molecule capable of binding to human T-cell immunoglobulin domain and mucin domain 3 (TIM-3), comprising:

(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 10; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(b) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 4; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(c) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 25; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(d) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 24; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(e) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 31; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14; or

(f) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 30; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a

VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

2. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 10; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14.

3. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 4; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

4. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 25; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14.

5. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 24; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

6. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 31; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a

VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14.

7. The antibody molecule of claim 1, comprising a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 30; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

8. The antibody molecule of any of claims 1-7, wherein said antibody molecule is a humanized antibody molecule.

9. The antibody molecule of any of claims 1-8, wherein said antibody molecule is a monospecific antibody molecule.

10. The antibody molecule of any of claims 1-8, wherein said antibody molecule is a bispecific antibody molecule.

11. The antibody molecule of claim 10, wherein said antibody molecule has a first binding specificity for TIM-3 and a second binding specificity for PD-1, LAG-3, CEACAM-1, CEACAM-5, PD-L1 or PD-L2.

12. The antibody molecule of any of claims 1-11, wherein said antibody molecule comprises an antigen binding fragment of an antibody.

13. The antibody molecule of claim 12, wherein said antibody molecule comprises a half antibody or antigen binding fragment of a half antibody.

14. The antibody molecule of any of claims 1-13, which is a Fab, F(ab')2, Fv, or a single chain Fv fragment (scFv).

AMENDED SHEET (ARTICLE 19)

15. The antibody molecule of any of claims 1-14, which binds an IgV domain of TIM-3.

16. The antibody molecule of any of claims 1-15, which comprises a heavy chain variable domain comprising an amino acid sequence at least 85% identical to any of SEQ ID NOs: 1, 16, 26, 32, 36, 44, 48, 52, 60, 68, 72, 76, 80, 84, 92, or 100.

17. The antibody molecule of any of claims 1-16, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 1, 16, 26, 32, 36, 44, 48, 52, 60, 68, 72, 76, 80, 84, 92, or 100.

18. The antibody molecule of any of claims 1-17, which comprises a light chain variable domain comprising an amino acid sequence at least 85% identical to any of SEQ ID NOs: 2, 20, 40, 56, 64, 88, 96, or 104.

19. The antibody molecule of any of claims 1-18, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 2, 20, 40, 56, 64, 88, 96, or 104.

20. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 1.

21. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16.

22. The antibody molecule of any of claims 1-21, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 121.

23. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26.

24. The antibody molecule of any one of claims 1-19 or 23, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 28.

25. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 32.

26. The antibody molecule of any one of claims 1-19 or 25, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 34.

27. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 36.

28. The antibody molecule of any one of claims 1-19 or 27, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 38 or SEQ ID NO: 116.

29. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 44.

30. The antibody molecule of any one of claims 1-19 or 29, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 46.

31. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 48.

32. The antibody molecule of any one of claims 1-19 or 31, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 50.

33. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 52.

34. The antibody molecule of any one of claims 1-19 or 33, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 54.

35. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60.

36. The antibody molecule of any one of claims 1-19 or 35, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 62.

37. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 68.

38. The antibody molecule of any one of claims 1-19 or 37, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 70.

39. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 72.

40. The antibody molecule of any one of claims 1-19 or 39, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 74.

41. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76.

42. The antibody molecule of any one of claims 1-19 or 41, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 78.

43. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80.

44. The antibody molecule of any one of claims 1-19 or 43, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 82.

45. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 84.

46. The antibody molecule of any one of claims 1-19 or 45, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 86.

47. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 92.

48. The antibody molecule of any one of claims 1-19 or 47, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 94.

49. The antibody molecule of any one of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 100.

50. The antibody molecule of any one of claims 1-19 or 49, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102.

51. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

52. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

53. The antibody molecule of any of claims 1-52, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 22.

AMENDED SHEET (ARTICLE 19)

54. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

55. The antibody molecule of any of claims 1-50 or 54, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 42.

56. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

57. The antibody molecule of any of claims 1-50 or 56, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 58.

58. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

59. The antibody molecule of any of claims 1-50 or 58, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 66.

60. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88.

61. The antibody molecule of any of claims 1-50 or 60, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 90.

62. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 96.

63. The antibody molecule of any of claims 1-50 or 62, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 98.

64. The antibody molecule of any of claims 1-50, which comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 104.

65. The antibody molecule of any of claims 1-50 or 64, which comprises a light chain comprising the amino acid sequence of SEQ ID NO: 106.

66. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

67. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

68. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

69. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 32 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

70. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

71. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 44 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

AMENDED SHEET (ARTICLE 19)

72. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 48 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

73. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20.

74. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40.

75. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

76. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

77. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

78. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

79. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

80. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 72 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

81. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

82. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

83. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

84. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 72 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56.

85. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

86. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64.

AMENDED SHEET (ARTICLE 19)

87. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 84 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88.

88. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 96.

89. The antibody molecule of any of claims 1-19, which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 100 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 104.

90. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

91. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 28 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

92. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 34 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

93. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain comprising the amino acid sequence of SEQ ID NO: 42.

94. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 46 and a light chain comprising the amino acid sequence of SEQ ID NO: 42.

AMENDED SHEET (ARTICLE 19)

95. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 50 and a light chain comprising the amino acid sequence of SEQ ID NO: 42.

96. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 116 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

97. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 42.

98. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 54 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

99. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 62 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

100. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 54 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

101. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 62 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

102. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 70 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

103. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 74 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

104. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 78 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

105. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 82 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

106. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 70 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

107. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 74 and a light chain comprising the amino acid sequence of SEQ ID NO: 58.

108. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 78 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

109. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 82 and a light chain comprising the amino acid sequence of SEQ ID NO: 66.

110. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 86 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

111. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 94 and a light chain comprising the amino acid sequence of SEQ ID NO: 98.

112. The antibody molecule of any of claims 1-19, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 106.

113. The antibody molecule of any of claims 1-112, which comprises a heavy chain constant region selected from IgG1, IgG2, IgG3, and IgG4.

114. The antibody molecule of claim 113, which comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda.

115. The antibody molecule of claim 113 or 114, which comprises a human IgG4 heavy chain constant region with a mutation at position 228 according to EU numbering or position 108 of SEQ ID NO: 108 or 110 and a kappa light chain constant region.

116. The antibody molecule of claim 113 or 114, which comprises a human IgG4 heavy chain constant region with a Serine to Proline mutation at position 228 according to EU numbering or position 108 of SEQ ID NO: 108 or 110 and a kappa light chain constant region.

117. The antibody molecule of claim 113 or 114, which comprises a human IgG1 heavy chain constant region with an Asparagine to Alanine mutation at position 297 according to EU numbering or position 180 of SEQ ID NO: 112 and a kappa light chain constant region.

118. The antibody molecule of claim 113 or 114, which comprises a human IgG1 heavy chain constant region with an Aspartate to Alanine mutation at position 265 according to EU numbering or position 148 of SEQ ID NO: 113 and Proline to Alanine mutation at position 329 according to EU numbering or position 212 of SEQ ID NO: 113, and a kappa light chain constant region.

119. The antibody molecule of claim 113 or 114, which comprises a human IgG1 heavy chain constant region with a Leucine to Alanine mutation at position 234 according to EU numbering or position 117 of SEQ ID NO: 114 and Leucine to Alanine mutation at position 235 according to EU numbering or position 118 of SEQ ID NO: 114, and a kappa light chain constant region.

120. The antibody molecule of any of claims 1-118, which is capable of binding to human TIM-3 with a dissociation constant (K_D) of less than about 0.5 nM.

121. The antibody molecule of any of claims 1-120, which is capable of reducing binding of TIM-3 to PtdSer, HMGB1, CEACAM-1, or a combination thereof, or a cell that expresses PtdSer, HMGB1, CEACAM-1, or a combination thereof.

122. The antibody molecule of any of claims 1-121, which is capable of enhancing an antigen-specific T cell response.

123. An isolated antibody molecule that binds to the same epitope as, or an epitope that overlaps with, the epitope of a monoclonal antibody to human T-cell immunoglobulin domain and mucin domain 3 (TIM-3), wherein the monoclonal antibody comprises:

(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 10; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(b) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 4; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(c) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 25; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(d) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 24; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(e) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 31; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14; or

(f) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 30; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8, wherein:

(1) the antibody molecule binds to one, two, three, or all of: the two residues adjacent to the N-terminus of the A strand (Val24 and Glu25 in human TIM-3), the BC loop, the CC' loop, or the G strand of human TIM-3; and

(2) the antibody molecule has one, two, three, four, five, six, seven or all of the following properties:

(i) reduces PtdSer-dependent membrane penetration of TIM-3;

(ii) reduces binding of TIM-3 to one, two, or all of PtdSer, HMGB1, or CEACAM-1;

(iii) does not inhibit binding of TIM-3 to Galectin-9;

(iv) competes with CEACAM-1 for binding to one, two, or all of Cys58, Asn119 and Lys122 of TIM-3;

(v) reduces the formation of a hydrogen bond between Lys122 of TIM-3 and Asn42 of CEACAM-1;

(vi) competes with PtdSer for binding to the FG loop and the CC' loop of TIM-3;

(vii) competes with HMGB1 for binding to Glu62 of TIM-3; or

(viii) does not compete with Galectin-9 for binding to TIM-3.

124. The antibody molecule of claim 123, wherein the antibody molecule further binds to one, two, three, or all of: the A strand, the EF loop, the F strand, or the FG loop.

125. The antibody molecule of claim 123 or 124, wherein the antibody molecule further binds to one, two, three, or all of: the third residue N-terminal to the A strand (Glu23 in human TIM-3), the C strand, the C'C'' loop, or the C'' strand.

126. The antibody molecule of any of claims 123-125, wherein the antibody molecule binds to one or both of residues Val24 and Glu25 adjacent to the N-terminus of the A strand; residue Thr41 within the BC loop; four, five, six, seven, or all of residues Glu121, Lys122, Phe123, Asn124, Leu125, Lys126, Leu127, and Val128 within the G strand; and three, four, five, or all of residues Gly56, Ala57, Cys58, Pro59, Val60, and Phe61 within the CC' loop.

127. The antibody molecule of any of claims 123-126, wherein the antibody molecule binds to residues Val24 and Glu25 adjacent to the N-terminus of the A strand; residue Thr41 within the BC loop; residues Glu121, Lys122, Phe123, Asn124, Leu125, Lys126, Leu127, and Val128 within the G strand; and residues Gly56, Ala57, Cys58, Pro59, Val60, and Phe61 within the CC' loop.

128. The antibody molecule of any of claims 123-127, wherein the antibody molecule further binds to one or more residues chosen from: residue Tyr26 within the A strand, residues

AMENDED SHEET (ARTICLE 19)

Phe39 and Tyr40 within the BC loop; residue Ser105 within the EF loop; residues Gly106 and Ile107 within the F strand; and residues Asn119 and Asp120 within the FG loop.

129. The antibody molecule of any of claims 123-128, wherein the antibody molecule further binds to residue Tyr26 within the A strand, residues Phe39 and Tyr40 within the BC loop; residue Ser105 within the EF loop; residues Gly106 and Ile107 within the F strand; and residues Asn119 and Asp120 within the FG loop.

130. The antibody molecule of any of claim 123-129, wherein the antibody molecule further binds to one or more residues chosen from: residue Glu23 N-terminal to the A strand; residues Pro42, Ala43, Ala44, Pro45, Gly46, Asn47, Leu48, Val49, and Pro50 within the BC loop; residues Val51, Cys52, Trp53, Gly54, and Lys55 within the C strand; residues Arg73 and Asp74 with the C'C'' loop; and residues Val75, Asn76, and Tyr77 in the C" strand.

131. The antibody molecule of any of claim 123-130, wherein the antibody molecule further binds to residue Glu23 N-terminal to the A strand; residues Pro42, Ala43, Ala44, Pro45, Gly46, Asn47, Leu48, Val49, and Pro50 within the BC loop; residues Val51, Cys52, Trp53, Gly54, and Lys55 within the C loop; residues Arg73 and Asp74 with the C'C'' strand; and residues Val75, Asn76, and Tyr77 in the C" strand.

132. The antibody molecule of any of claims 123-131, wherein the antibody molecule reduces PtdSer-dependent membrane penetration of TIM-3.

133. The antibody molecule of any of claims 123-132, wherein the antibody molecule reduces binding of TIM-3 to one, two, or all of PtdSer, HMGB1, or CEACAM-1.

134. The antibody molecule of any of claims 123-133, wherein the antibody molecule does not inhibit binding of TIM-3 to Galectin-9.

AMENDED SHEET (ARTICLE 19)

135. The antibody molecule of any of claims 123-134, wherein the antibody molecule competes with CEACAM-1 for binding to one, two, or all of Cys58, Asn119 and Lys122 of TIM-3.

136. The antibody molecule of claim 135, wherein the antibody molecule reduces the formation of a hydrogen bond between Lys122 of TIM-3 and Asn42 of CEACAM-1.

137. The antibody molecule of any of claims 123-136, wherein the antibody molecule competes with PtdSer for binding to the FG loop and the CC' loop of TIM-3.

138. The antibody molecule of any of claims 123-137, wherein the antibody molecule competes with HMGB1 for binding to Glu62 of TIM-3.

139. The antibody molecule of any of claims 123-138, wherein the antibody molecule does not compete with Galectin-9 for binding to TIM-3.

140. A pharmaceutical composition comprising the isolated antibody molecule of any of claims 1-139, and a pharmaceutically acceptable carrier, excipient or stabilizer.

141. An isolated nucleic acid encoding the antibody heavy or light chain variable region of the antibody molecule of any of claims 1-139.

142. An isolated nucleic acid encoding heavy chain CDRs 1-3, wherein said nucleic acid comprises a nucleotide sequence encoding SEQ ID NOs: 3, 9, 4, 10, 24, 25, 30, 31, or 5.

143. An isolated nucleic acid encoding light chain CDRs 1-3, wherein said nucleic acid comprises a nucleotide sequence encoding SEQ ID NOs: 6, 12, 7, 13, 8, or 14.

144. The nucleic acid of claim 142, further comprising a nucleotide sequence encoding a heavy chain variable domain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 11, 17, 29, 33, 37, 45, 49, 53, 61, 69, 73, 77, 81, 85, 93, 101, 115, or 120.

145. The nucleic acid of claim 144, further comprising a nucleotide sequence encoding a heavy chain variable domain, wherein said nucleotide sequence comprises any of SEQ ID NO: 11, 17, 29, 33, 37, 45, 49, 53, 61, 69, 73, 77, 81, 85, 93, 101, 115, or 120.

146. The nucleic acid of claim 142, further comprising a nucleotide sequence encoding a heavy chain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 19, 29, 35, 39, 47, 51, 55, 63, 71, 75, 79, 83, 87, 95, 103, 117, or 122.

147. The nucleic acid of claim 146, further comprising a nucleotide sequence encoding a heavy chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 19, 29, 35, 39, 47, 51, 55, 63, 71, 75, 79, 83, 87, 95, 103, 117, or 122.

148. The nucleic acid of claim 143, which further comprises a nucleotide sequence encoding a light chain variable domain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 15, 21, 41, 57, 65, 89, 97, 105, 118, 123, 125, or 127.

149. The nucleic acid of claim 148, which further comprises a nucleotide sequence encoding a light chain variable domain, wherein said nucleotide sequence comprises any of SEQ ID NO: 15, 21, 41, 57, 65, 89, 97, 105, 118, 123, 125, or 127.

150. The nucleic acid of claim 143, further comprising a nucleotide sequence encoding a light chain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 23, 43, 59, 67, 91, 99, 107, 119, 124, 126, 128.

151. The nucleic acid of claim 150, further comprising a nucleotide sequence encoding a light chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 23, 43, 59, 67, 91, 99, 107, 119, 124, 126, 128.

152. An expression vector comprising the nucleic acid of any of claims 141-151.

153. A host cell comprising the nucleic acid of any of claims 141-151.

154. A method of producing an antibody molecule or fragment thereof, comprising culturing the host cell of claim 153 under conditions suitable for gene expression.

155. A method of stimulating an immune response in a subject, comprising administering to a subject in need thereof an isolated antibody molecule of any of claims 1-139, or a pharmaceutical composition of claim 140, in an amount effective to stimulate the immune response.

156. A method of treating a cancer, comprising administering to a subject in need thereof an isolated antibody molecule of any of claims 1-139, or a pharmaceutical composition of claim 142, in an amount effective to treat the cancer.

157. The method of claim 156, wherein the cancer is chosen from a lung cancer, a squamous cell lung cancer, a melanoma, a renal cancer, a breast cancer, an IM-TN breast cancer, a colorectal cancer, a leukemia, or a metastatic lesion of the cancer.

158. The method of any of claims 155-157, wherein the antibody molecule is administered in combination with a second therapeutic agent or procedure.

159. The method of claim 158, wherein the second therapeutic agent or procedure is chosen from one or more of chemotherapy, a targeted anti-cancer therapy, an oncolytic drug, a cytotoxic agent, an immune-based therapy, a cytokine, surgical procedure, a radiation procedure, an activator of a costimulatory molecule, an inhibitor of an inhibitory molecule, a vaccine, or a cellular immunotherapy.

160. The method of claim 158 or 159, wherein the antibody molecule is administered in combination with an agonist of a costimulatory molecule chosen from one or more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR,

CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand.

161. The method of claim 158 or 159, wherein the antibody molecule is administered in combination with an inhibitor of an immune checkpoint molecule chosen from one or more of PD-1, PD-L1, PD-L2, CTLA-4, LAG-3, CEACAM-1, CEACAM-5, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR.

162. A method of treating an infectious disease, comprising administering to a subject in need thereof an isolated antibody molecule of any of claims 1-139, or a pharmaceutical composition of claim 140, in an amount effective to treat the infectious disease.

163. A method of detecting TIM-3 in a biological sample, comprising (i) contacting the sample or the subject with an isolated antibody molecule of any of claims 1-139 under conditions that allow interaction of the antibody molecule and the polypeptide to occur, and (ii) detecting formation of a complex between the antibody molecule and the sample or the subject.

164. An antibody molecule of any of claims 1-139, or a pharmaceutical composition of claim 140, for use in treating a cancer or an infectious disease in a subject.

165. Use of an antibody molecule of any of claims 1-139, or a pharmaceutical composition of claim 140, in the manufacture of a medicament for treating a cancer or an infectious disease in a subject.

AMENDED SHEET (ARTICLE 19)

CLAIMS

1. An isolated antibody molecule capable of binding to human T-cell immunoglobulin domain and mucin domain 3 (TIM-3), comprising:

(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 10; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(b) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 4; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(c) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 25; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(d) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 24; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(e) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 31; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14; or

(f) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 30; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a

VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8.

2. The antibody molecule of claim 1, wherein said antibody molecule is a humanized antibody molecule, and/or a monospecific antibody or a bispecific antibody molecule.

3. The antibody molecule of claim 1 or 2, wherein said antibody molecule has a first binding specificity for TIM-3 and a second binding specificity for PD-1, LAG-3, CEACAM-1, CEACAM-5, PD-L1 or PD-L2; and/or

wherein said antibody molecule comprises an antigen binding fragment of an antibody, e.g.,

a half antibody or antigen binding fragment of a half antibody.

4. The antibody molecule of any of claims 1-3, which is a Fab, F(ab')2, Fv, or a single chain Fv fragment (scFv); or comprises

a heavy chain constant region selected from IgG1, IgG2, IgG3, and IgG4, and/or

a light chain constant region chosen from the light chain constant regions of kappa or lambda.

5. The antibody molecule of any of claims 1-4, which comprises:

a heavy chain variable domain comprising an amino acid sequence chosen from SEQ ID NO: 1, 16, 26, 32, 36, 44, 48, 52, 60, 68, 72, 76, 80, 84, 92, or 100, or an amino acid sequence at least 85% identical to any of SEQ ID NOs: 1, 16, 26, 32, 36, 44, 48, 52, 60, 68, 72, 76, 80, 84, 92, or 100; and/or

a light chain variable domain comprising an amino acid sequence chosen from SEQ ID NO: 2, 20, 40, 56, 64, 88, 96, or 104, or an amino acid sequence at least 85% identical to any of SEQ ID NOs: 2, 20, 40, 56, 64, 88, 96, or 104.

6. The antibody molecule of any one of claims 1-5, which comprises:

a heavy chain variable domain comprising an amino acid sequence chosen from SEQ ID NO: 1, 16, 26, 32, 36, 44, 48, 52, 60, 68, 72, 76, 80, 84, 92, or 100; and/or

a light chain variable domain comprising an amino acid sequence chosen from SEQ ID NO: 2, 20, 40, 56, 64, 88, 96, or 104.

7. The antibody molecule of any of claims 1-6, which comprises:

a heavy chain comprising an amino acid sequence chosen from SEQ ID NO: 18, 121, 28, 34, 38, 116, 46, 50, 54, 62, 70, 74, 78, 82, 86, 94, or 102; and/or

a light chain comprising an amino acid sequence chosen from SEQ ID NO: 22, 42, 58, 66, 90, 98, or 106.

8. The antibody molecule of any of claims 1-6, which comprises:

(a) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 2;

(b) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20;

(c) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20;

(d) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 32 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20;

(e) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40;

(f) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 44 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40;

(g) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 48 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40;

(h) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 20;

(i) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40;

(j) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56;

(k) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56;

(l) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64;

(m) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64;

(n) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64;

(o) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 72 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64;

(p) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56;

(q) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56;

(r) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56;

(s) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 72 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 56;

(t) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64;

(u) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64;

(v) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 84 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88;

(w) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 96; or

(x) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 100 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 104.

9. The antibody molecule of any of claims 1-5, which comprises:

(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 22;

(b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 28 and a light chain comprising the amino acid sequence of SEQ ID NO: 22;

(c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 34 and a light chain comprising the amino acid sequence of SEQ ID NO: 22;

(d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain comprising the amino acid sequence of SEQ ID NO: 42;

(e) a heavy chain comprising the amino acid sequence of SEQ ID NO: 46 and a light chain comprising the amino acid sequence of SEQ ID NO: 42;

(f) a heavy chain comprising the amino acid sequence of SEQ ID NO: 50 and a light chain comprising the amino acid sequence of SEQ ID NO: 42;

(g) a heavy chain comprising the amino acid sequence of SEQ ID NO: 116 and a light chain comprising the amino acid sequence of SEQ ID NO: 22;

(h) a heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 42;

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 54 and a light chain comprising the amino acid sequence of SEQ ID NO: 58;

(j) a heavy chain comprising the amino acid sequence of SEQ ID NO: 62 and a light chain comprising the amino acid sequence of SEQ ID NO: 58;

(k) a heavy chain comprising the amino acid sequence of SEQ ID NO: 54 and a light chain comprising the amino acid sequence of SEQ ID NO: 66;

(l) a heavy chain comprising the amino acid sequence of SEQ ID NO: 62 and a light chain comprising the amino acid sequence of SEQ ID NO: 66;

(m) a heavy chain comprising the amino acid sequence of SEQ ID NO: 70 and a light chain comprising the amino acid sequence of SEQ ID NO: 66;

(n) a heavy chain comprising the amino acid sequence of SEQ ID NO: 74 and a light chain comprising the amino acid sequence of SEQ ID NO: 66;

(o) a heavy chain comprising the amino acid sequence of SEQ ID NO: 78 and a light chain comprising the amino acid sequence of SEQ ID NO: 58;

(p) a heavy chain comprising the amino acid sequence of SEQ ID NO: 82 and a light chain comprising the amino acid sequence of SEQ ID NO: 58;

(q) a heavy chain comprising the amino acid sequence of SEQ ID NO: 70 and a light chain comprising the amino acid sequence of SEQ ID NO: 58;

(r) a heavy chain comprising the amino acid sequence of SEQ ID NO: 74 and a light chain comprising the amino acid sequence of SEQ ID NO: 58;

(s) a heavy chain comprising the amino acid sequence of SEQ ID NO: 78 and a light chain comprising the amino acid sequence of SEQ ID NO: 66;

(t) a heavy chain comprising the amino acid sequence of SEQ ID NO: 82 and a light chain comprising the amino acid sequence of SEQ ID NO: 66;

(u) a heavy chain comprising the amino acid sequence of SEQ ID NO: 86 and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 94 and a light chain comprising the amino acid sequence of SEQ ID NO: 98; or

(w) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 106.

10. The antibody molecule of any of claims 1-9, which comprises:

(a) a human IgG4 heavy chain constant region with a mutation at position 228 according to EU numbering or position 108 of SEQ ID NO: 108 or 110 and a kappa light chain constant region;

(b) a human IgG4 heavy chain constant region with a Serine to Proline mutation at position 228 according to EU numbering or position 108 of SEQ ID NO: 108 or 110 and a kappa light chain constant region;

(c) a human IgG1 heavy chain constant region with an Asparagine to Alanine mutation at position 297 according to EU numbering or position 180 of SEQ ID NO: 112 and a kappa light chain constant region;

(d) a human IgG1 heavy chain constant region with an Aspartate to Alanine mutation at position 265 according to EU numbering or position 148 of SEQ ID NO: 113 and Proline to Alanine mutation at position 329 according to EU numbering or position 212 of SEQ ID NO: 113, and a kappa light chain constant region; or

(e) a human IgG1 heavy chain constant region with a Leucine to Alanine mutation at position 234 according to EU numbering or position 117 of SEQ ID NO: 114 and Leucine to Alanine mutation at position 235 according to EU numbering or position 118 of SEQ ID NO: 114, and a kappa light chain constant region.

11. The antibody molecule of any of claims 1-10, which has one, two, three, or all of the following properties:

(a) is capable of binding to human TIM-3 with a dissociation constant (K_D) of less than about 0.5 nM;

(b) is capable of reducing:

(i) binding of TIM-3 to phosphatidylserine (PtdSer), HMGB1, CEACAM-1, Semaphorin 4-A, or a combination thereof, or a cell that expresses PtdSer, HMGB1, CEACAM-1, Semaphorin 4-A, or a combination thereof; or

(ii) PtdSer-mediated membrane penetration of TIM-3.

(c) is capable of enhancing an antigen-specific T cell response; or

(d) binds an IgV domain of TIM-3.

12. An isolated antibody molecule that binds to the same epitope as, or an epitope that overlaps with, the epitope as a monoclonal antibody to human T-cell immunoglobulin domain and mucin domain 3 (TIM-3), wherein the monoclonal antibody comprises:

(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 10; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(b) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 4; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(c) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 25; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;

(d) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 24; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8;

(e) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 9; a VHCDR2 amino acid sequence of SEQ ID NO: 31; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14; or

(f) a VH comprising a VHCDR1 amino acid sequence chosen from SEQ ID NO: 3; a VHCDR2 amino acid sequence of SEQ ID NO: 30; and a VHCDR3 amino acid sequence of SEQ ID NO: 5; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO: 7, and a VLCDR3 amino acid sequence of SEQ ID NO: 8, wherein

(1) the antibody molecule binds to one, two, three, or all of: the two residues adjacent to the N-terminus of the A strand (Val24 and Glu25 in human TIM-3), the BC loop, the CC' loop, or the G strand of human TIM-3; and

(2) the antibody molecule has one, two, three, four, five, six, seven or all of the following properties:

(i) reduces PtdSer-dependent membrane penetration of TIM-3;

(ii) reduces binding of TIM-3 to one, two, or all of PtdSer, HMGB1, or CEACAM-1;

(iii) does not inhibit binding of TIM-3 to Galectin-9;

(iv) competes with CEACAM-1 for binding to one, two, or all of Cys58, Asn119 and Lys122 of TIM-3;

(v) reduces the formation of a hydrogen bond between Lys122 of TIM-3 and Asn42 of CEACAM-1;

(vi) competes with PtdSer for binding to the FG loop and the CC' loop of TIM-3;

(vii) competes with HMGB1 for binding to Glu62 of TIM-3; or

(viii) does not compete with Galectin-9 for binding to TIM-3.

13. The antibody molecule of claim 12, wherein the antibody molecule binds to one, two, three, four, five, six, seven, eight, or all of the following:

(a) one, two, three, or all of: the two residues adjacent to the N-terminus of the A strand (Val24 and Glu25 in human TIM-3), the BC loop, the CC' loop, or the G strand of human TIM-3;

(b) one, two, three, or all of: the A strand, the EF loop, the F strand, or the FG loop;

(c) one, two, three, or all of: the third residue N-terminal to the A strand (Glu23 in human TIM-3), the C strand, the C'C'' loop, or the C'' strand;

(d) one or both of residues Val24 and Glu25 adjacent to the N-terminus of the A strand; residue Thr41 within the BC loop; four, five, six, seven, or all of residues Glu121, Lys122, Phe123, Asn124, Leu125, Lys126, Leu127, and Val128 within the G strand; and three, four, five, or all of residues Gly56, Ala57, Cys58, Pro59, Val60, and Phe61 within the CC' loop;

(e) residues Val24 and Glu25 adjacent to the N-terminus of the A strand; residue Thr41 within the BC loop; residues Glu121, Lys122, Phe123, Asn124, Leu125, Lys126, Leu127, and Val128 within the G strand; and residues Gly56, Ala57, Cys58, Pro59, Val60, and Phe61 within the CC' loop;

(f) one or more residues chosen from: residue Tyr26 within the A strand, residues Phe39 and Tyr40 within the BC loop; residue Ser105 within the EF loop; residues Gly106 and Ile107 within the F strand; and residues Asn119 and Asp120 within the FG loop;

(g) residue Tyr26 within the A strand, residues Phe39 and Tyr40 within the BC loop; residue Ser105 within the EF loop; residues Gly106 and Ile107 within the F strand; and residues Asn119 and Asp120 within the FG loop;

(h) one or more residues chosen from: residue Glu23 N-terminal to the A strand; residues Pro42, Ala43, Ala44, Pro45, Gly46, Asn47, Leu48, Val49, and Pro50 within the BC loop; residues Val51, Cys52, Trp53, Gly54, and Lys55 within the C strand; residues Arg73 and Asp74 with the C'C'' loop; and residues Val75, Asn76, and Tyr77 in the C" strand; and/or

(i) residue Glu23 N-terminal to the A strand; residues Pro42, Ala43, Ala44, Pro45, Gly46, Asn47, Leu48, Val49, and Pro50 within the BC loop; residues Val51, Cys52, Trp53, Gly54, and Lys55 within the C loop; residues Arg73 and Asp74 with the C'C'' strand; and residues Val75, Asn76, and Tyr77 in the C" strand.

14. A pharmaceutical composition comprising the isolated antibody molecule of any of claims 1-13 and a pharmaceutically acceptable carrier, excipient or stabilizer.

15. An isolated nucleic acid encoding the antibody heavy or light chain variable region of the antibody molecule of any of claims 1-13.

16. An isolated nucleic acid encoding heavy chain CDRs 1-3 and/or light chain CDRs 1-3, wherein said nucleic acid comprises a nucleotide sequence encoding SEQ ID NOs: 3-10, 12-14, 24, 25, 30, or 31.

17. The nucleic acid of claim 16, further comprising:

a nucleotide sequence encoding a heavy chain variable domain, wherein said nucleotide sequence comprises any of SEQ ID NO: 11, 17, 29, 33, 37, 45, 49, 53, 61, 69, 73, 77, 81, 85, 93, 101, 115, or 120, or is at least 85% identical to any of SEQ ID NO: 11, 17, 29, 33, 37, 45, 49, 53, 61, 69, 73, 77, 81, 85, 93, 101, 115, or 120; and/or

a nucleotide sequence encoding a light chain variable domain, wherein said nucleotide sequence comprises any of SEQ ID NO: 15, 21, 41, 57, 65, 89, 97, 105, 118, 123, 125, or 127, or is at least 85% identical to any of SEQ ID NO: 15, 21, 41, 57, 65, 89, 97, 105, 118, 123, 125, or 127.

18. The nucleic acid of claim 16, further comprising:

a nucleotide sequence encoding a heavy chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 19, 29, 35, 39, 47, 51, 55, 63, 71, 75, 79, 83, 87, 95, 103, 117, or 122, or is at least 85% identical to any of SEQ ID NO: 19, 29, 35, 39, 47, 51, 55, 63, 71, 75, 79, 83, 87, 95, 103, 117, or 122; and/or

a nucleotide sequence encoding a light chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 23, 43, 59, 67, 91, 99, 107, 119, 124, 126, 128, or is at least 85% identical to any of SEQ ID NO: 23, 43, 59, 67, 91, 99, 107, 119, 124, 126, 128.

19. An expression vector comprising the nucleic acid of any of claims 15-18.

20. A host cell comprising the nucleic acid of any of claims 15-18.

21. A method of producing an antibody molecule or fragment thereof, comprising culturing the host cell of claim 20 under conditions suitable for gene expression.

22. A method of detecting TIM-3 in a biological sample, comprising (i) contacting the sample or the subject (and optionally, a reference sample or subject) with an isolated antibody molecule of any of claims 1-13 under conditions that allow interaction of the antibody molecule and the polypeptide to occur, and (ii) detecting formation of a complex between the antibody molecule and the sample or the subject (and optionally, the reference sample or subject).

23. An antibody molecule of any of claims 1-13, or a pharmaceutical composition of claim 14, for use in the stimulation of an immune response or the treatment of a cancer or an infectious disease in a subject.

24. The use of an antibody molecule, or a pharmaceutical composition as claimed in claim 23, wherein the cancer is chosen from a lung cancer, a melanoma, a renal cancer, a liver cancer, a prostate cancer, a breast cancer, a head and neck cancer, a colorectal cancer, a pancreatic cancer, a brain cancer, a hematological cancer, or a metastatic lesion of the cancer,

optionally, wherein:

(a) the lung cancer is chosen from a non-small cell lung cancer (NSCLC), a lung adenocarcinoma, a squamous cell lung carcinoma, or a small cell lung cancer;

(b) the melanoma is chosen from an advanced melanoma, an unresectable melanoma, a metastatic melanoma, a melanoma with a BRAF mutation, a melanoma with an NRAS mutation, a cutaneous melanoma, or an intraocular melanoma;

(c) the renal cancer is chosen from a renal cell carcinoma (RCC), a metastatic renal cell carcinoma, a clear cell renal cell carcinoma (CCRCC), a kidney clear cell carcinoma, or a kidney papillary cell carcinoma; or

(d) the hematologic cancer is chosen from a lymphoma (e.g., a non-Hodgkin lymphoma), a myeloma, or a leukemia.

25. The use of an antibody molecule, or a pharmaceutical composition as claimed in claim 23 or 24, wherein the antibody molecule or pharmaceutical composition is to be used in combination with a second therapeutic agent or procedure,

optionally, wherein the second therapeutic agent or procedure is chosen from one or more of a chemotherapy, a targeted anti-cancer therapy, an oncolytic drug, a cytotoxic agent, an immune-based therapy, a cytokine, surgical procedure, a radiation procedure, an activator of a costimulatory molecule, an inhibitor of an inhibitory molecule, a vaccine, or a cellular immunotherapy;

optionally, wherein the antibody molecule is to be used in combination with:

(a) an agonist of a costimulatory molecule chosen from one or more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand; or

(b) an inhibitor of an immune checkpoint molecule chosen from one or more of PD-1, PD-L1, PD-L2, CTLA-4, LAG-3, CEACAM-1, CEACAM-5, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR.

26. The use of an antibody molecule, or a pharmaceutical composition as claimed in any of claims 23-25, wherein the antibody molecule or pharmaceutical composition is to be used in combination with one or more of the following:

(a) an inhibitor of PD-1, optionally, wherein the inhibitor of PD-1 is an anti-PD-1 antibody molecule or a fusion protein or chosen from MDX-1106, Merck 3475, CT-011, AMP-224, or AMP-514;

(c) an inhibitor of PD-L1, optionally, wherein the inhibitor of PD-L1 is an anti-PD-L1 antibody molecule or a fusion protein or chosen from YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1105;

(d) an inhibitor of LAG-3, optionally, wherein the inhibitor of LAG-3 is an anti-LAG-3 antibody molecule or a fusion protein;

(e) an agonist of GITR, optionally, wherein the agonist of GITR is an anti-GITR antibody molecule or a fusion protein;

(f) a chemotherapy for the treatment of a lung cancer, optionally, wherein the chemotherapy is a platinum doublet therapy;

(g) an indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibitor for the treatment of a lung cancer, optionally, wherein the IDO inhibitor is INCB24360;

(h) an inhibitor of CTLA-4 for the treatment of a lung cancer or a melanoma, optionally, wherein the inhibitor of CTLA-4 is an anti-CTLA-4 antibody (e.g., ipilimumab) or a soluble ligand of CTLA-4, optionally, wherein the antibody molecule, or pharmaceutical composition, is to be used further in combination with a BRAF inhibitor (e.g., vemurafenib or dabrafenib);

(i) a MEK inhibitor for the treatment of a lung cancer, a melanoma, or a renal cancer;

(j) a cancer vaccine, optionally, wherein the cancer vaccine is a dendritic cell renal carcinoma (DC-RCC) vaccine;

(k) one or more of:

(i) an immune-based therapy, optionally, wherein the immune-based therapy comprises interleukin-2 or interferon-α;

(ii) a targeting agent, optionally, wherein the targeting agent is a VEGF inhibitor (e.g., an anti-VEGF antibody);

(iii) a VEGF tyrosine kinase inhibitor, optionally, wherein the VEGF tyrosine kinase inhibitor is chosen from sunitinib, sorafenib, axitinib, or pazopanib;

(iv) an RNAi inhibitor; or

(v) an inhibitor of a downstream mediator of VEGF signaling for the treatment of a renal cancer, optionally, wherein the inhibitor of a downstream mediator of VEGF signaling is an inhibitor of the mammalian target of rapamycin (mTOR), e.g., everolimus or temsirolimus;

(l) one, two or all of oxaliplatin, leucovorin or 5-FU, for the treatment of a lung cancer, a melanoma, or a renal cancer; or

(m) a tyrosine kinase inhibitor for the treatment of a renal cancer, optionally, wherein the tyrosine kinase inhibitor is axitinib.

27. The use of an antibody molecule, or a pharmaceutical composition as claimed in any of claims 23-26, wherein the subject has, or is identified as having, one or more of:

(a) a cancer that expresses TIM-3;

(b) a cancer that is positive for one, two, or all of PD-L1, CD8, or IFN-γ;

(c) a cancer that is triple positive for PD-L1, CD8, and IFN-γ; or

(d) a cancer that is Tumor Infiltrating Lymphocyte (TIL) positive.

28. The use of an antibody molecule, or a pharmaceutical composition as claimed in any of claims 23-27, wherein the antibody molecule or pharmaceutical composition is to be administered at a dose of about 0.1 to 30 mg/kg, e.g., 1 to 30 mg/kg or 1 to 5 mg/kg, optionally, wherein the antibody molecule or pharmaceutical composition is to be administered once a week to once every 2, 3, or 4 weeks or the antibody molecule or pharmaceutical composition is to be administered at a dose from about 10 to 20 mg/kg every other week.

29. The use of an antibody molecule, or pharmaceutical composition as claimed in any of claims 23-28, wherein the antibody molecule or pharmaceutical composition is to be used in combination with one or more of: 1) a protein kinase C (PKC) inhibitor; 2) a heat shock protein 90 (HSP90) inhibitor; 3) an inhibitor of a phosphoinositide 3-kinase (PI3K) and/or target of rapamycin (mTOR); 4) an inhibitor of cytochrome P450 (*e.g.*, a CYP17 inhibitor or a 17alpha-Hydroxylase/C17-20 Lyase inhibitor); 5) an iron chelating agent; 6) an aromatase inhibitor; 7) an inhibitor of p53, *e.g.*, an inhibitor of a p53/Mdm2 interaction; 8) an apoptosis inducer; 9) an angiogenesis inhibitor; 10) an aldosterone synthase inhibitor; 11) a smoothened (SMO) receptor inhibitor; 12) a prolactin receptor (PRLR) inhibitor; 13) a Wnt signaling inhibitor; 14) a CDK4/6 inhibitor; 15) a fibroblast growth factor receptor 2 (FGFR2)/fibroblast growth factor receptor 4 (FGFR4) inhibitor; 16) an inhibitor of macrophage colony-stimulating factor (M-CSF); 17) an inhibitor of one or more of c-KIT, histamine release, Flt3 (*e.g.*, FLK2/STK1) or PKC; 18) an inhibitor of one or more of VEGFR-2 (*e.g.*, FLK-1/KDR), PDGFRbeta, c-KIT or Raf kinase C; 19) a somatostatin agonist and/or a growth hormone release inhibitor; 20) an anaplastic lymphoma kinase (ALK) inhibitor; 21) an insulin-like growth factor 1 receptor (IGF-1R) inhibitor; 22) a P-Glycoprotein 1 inhibitor; 23) a vascular endothelial growth factor receptor (VEGFR) inhibitor; 24) a BCR-ABL kinase inhibitor; 25) an FGFR inhibitor; 26) an inhibitor of CYP11B2; 27) a HDM2 inhibitor, *e.g.*, an inhibitor of the HDM2-p53 interaction; 28) an inhibitor of a tyrosine kinase; 29) an inhibitor of c-MET; 30) an inhibitor of JAK; 31) an inhibitor of DAC; 32) an inhibitor of 11β-hydroxylase; 33) an inhibitor of IAP; 34) an inhibitor of PIM kinase; 35) an inhibitor of Porcupine; 36) an inhibitor of BRAF, *e.g.*, BRAF

V600E or wild-type BRAF; 37) an inhibitor of HER3; 38) an inhibitor of MEK; or 39) an inhibitor of a lipid kinase.

30. The use of an antibody molecule, or a pharmaceutical composition as claimed in any of claims 23-29, wherein the antibody molecule or pharmaceutical composition is to be used in combination with one or more of Compounds A1 to A51 as described in Table 6.

31. An antibody molecule of any of claims 1-13, or a pharmaceutical composition of claim 14, for use in the stimulation of an immune response or the treatment of a cancer or an infectious disease in a subject.